March 21, 2022 4:58pm

Before it was time to sell into strength as recommended this a.m.

Earnings: Caribou Therapeutics (CRBU -$0.62)

Financing: Applied Genetic Technologies (AGTC -$0.08 with an aftermarket -$0.46 decline) proposes offering

Pre-open indications: 8 Hits and 0 MISS

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

The multiple metrics says it all succinctly … just the facts

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read the facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed DOWN -201.94 points (-0.58%); the S&P closed DOWN -1.94 points (-0.04%) while the Nasdaq closed DOWN -55.38 points (-0.40%)

 

Henry’omics:

Indexes oscillated Monday with major averages hitting their lows of the day after Fed’s Chair Powell sounded alarms on surging inflation and vowed tough action.

  • Powell said Monday that “inflation is much too high’ and pledged to take “necessary steps” to bring prices under control. He noted rate hikes could go from the traditional 25 basis point moves to more aggressive 50 basis point increases if necessary. The comments come less than a week after the Fed raised interest rates for the first time since 2018. <CNBC>

 

This a.m.’s post, RegMed Investors’ (RMi) pre-open: “holding onto gains or evacuate from risk. The good times don’t always last, build cash positions as recent highs with partial sells.” …  https://www.regmedinvestors.com/articles/12350

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Monday opened negative at 5 up/29 downs, 1 flat, stayed negative at the mid-day at 1/33 and 1 flat, ending with a negative close of 2/31 and 2 flats;

 

Pre-open Indications: 8 Hits < Biostage (BSTG +$0.00); SELL into Strength: Sage Therapeutics (SAGE -$1.09), Editas Medicine (EDIT -$0.95), CRISPR Therapeutics (CRSP -$2.23), Intellia Therapeutics (NTLA -$2.37), Fate Therapeutics (FATE -$0.04), BioLife Solutions (BLFS -$1.64), Global Blood Therapeutics (GBT -$0.44)> 0 Miss >

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … 29 to date

 

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works closing flat ($0.00) on Monday with 5 shares traded after Friday’s 26 shares traded, Thursday’s jumping +$0.50, then +$0.30 then +$0.47 with 1,737 shares traded, Wednesday closed flat with 765 shares traded, Tuesday expressed decline of -$0.30 with 380 shares traded and last Monday’s flat with 28 shares traded

  • WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
  • A “zombie” company funded by non-U.S. Beijing, China entities
  • By use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering
  • BSTG is NOT going ANYWHERE without a cash inflow.

 

Key Metrics:

  • Monday - Sector volume was LOW with 1 of the 2-upside having higher than the 3-month average volume with LOW volume of 6 of 31-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB was down -1.34% and the XBI was down -3.41%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -0.29 points or -1.21% at 23.58

 

Jumping with share pricing momentum (2 of 2):

  • Voyager Therapeutics (VYGR +$0.59),
  • Brainstorm Cell Therapeutics (BCLI +$0.02),

Hammered in today’s market (15 of 31):

  • Beam Therapeutics (BEAM -$3.98),
  • Alnylam Pharmaceuticals (ALNY -$2.82),
  • Intellia Therapeutics (NTLA -$2.37),
  • CRISPR Therapeutics (CRSP -$2.23),
  • BioLife Solutions (BLFS -$1.64),
  • Vericel (VCEL -$1.62),
  • Sage Therapeutics (SAGE -$1.09),
  • Ultragenyx (RARE -$1.00),
  • Editas Medicine (EDIT -$0.95),
  • AxoGen (AXGN -$0.76),
  • Caribou Therapeutics (CRBU -$0.62),
  • Global Blood Therapeutics (GBT -$0.44),
  • Sangamo Therapeutics (SGMO -$0.39),
  • Ionis Pharmaceuticals (IONS -$0.33),
  • Mesoblast (MESO -$0.32),

Closing Flat:

  • Biostage (BSTG) and Homology Medicine (FIXX)

 

March, Q1/2022:

  • Monday closed negative with 2 incliners, 31 decliners and 2 flats
  • Friday closed positive with 28 incliners and 5 decliners and 2 flats

 

The BOTTOM LINE: As I stated this a.m., “it’s coming” and it came …” Caution is still in order. The sector should begin to struggle, with some equities slipping from highs. I say, cut or partially sell into strength without totally removing some names.”

What and which go up, also slip down; it’s sector physiology as risks go both ways.

Monday gave back gains after last week's advances, it was bound to happen as algorithms savored the heated sector.

Percentage gainers (2) ranged from +0.59% to +7.455 as compared to Friday’s (28) + 0.32% to +10.08% while the losses (31) ranged from -0.11% to -9.86% as compared to Friday’s (5) -0.20% to -12.88%.

Reiterating, “investors should remain cautious on adding extra risk in this time of conflict uncertainty.

Remember the adage, “It takes two to make a market"; that’s sellers and buyers.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Q4 and end-of-year earnings are still “gamy” than even I thought.

Earnings’ reporting coming:

·         Brainstorm Cell Therapeutics (BCLI), Monday, 3/28

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

 

WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it defines purpose that takes courage, resolve and patience to stay the course of asking the questions without response!